Based on these findings, it was proposed that impaired glucose metabolism in AD may contribute to disease pathogenesis by reducing tau O-GlcNAcylation and, consequently, increasing tau phosphorylation [143]. This evidence concerns the gene MAPT and Alzheimer disease.